The abstract is read at the publisher; the summary is JClub's.
Ribonucleotide reductase inhibition reverses FLT3 inhibitor resistance in NRAS-driven FLT3ITD+ acute myeloid leukemia, restoring FLT3i sensitivity across multiple in vitro models and xenografts.
- Why it matters: FLT3ITD+ AML commonly relapses due to acquired FLT3 inhibitor resistance, and reactivated RAS/MAPK signaling—often via NRAS—has left effective countermeasures lacking.
- What they did: The study tested RNR as a vulnerability in NRAS-driven, FLT3i-resistant FLT3ITD+ AML using pharmacologic RNR inhibitors and siRNA knockdown, then evaluated clofarabine in CDX and PDX xenograft models.
- The result: Clofarabine significantly overcomes NRAS mutation-driven FLT3i resistance and, combined with FLT3 inhibition, markedly suppresses progression and significantly prolongs survival in both CDX and PDX AML models.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.